Análisis de costo-efectividad de lenalidomida más terapia de soporte comparada con terapia de soporte sin lenalidomida para el tratamiento de pacientes con síndrome mielodisplásico y deleción 5q en Colombia

Vera Cala, Lina María; Cortés Aguilar, Alexandra; López Barbosa, Nahyr; Estrada Cañas, Ismael; Serrano Gómez, Sergio.
Bogotá; IETS; mayo 2016. 40 p. tab, graf.
Monografia em Espanhol | BRISA, LILACS | ID: biblio-846469

Documentos relacionados

  1. Real-world biologic and apremilast treatment patterns and healthcare costs in moderate-to-severe plaque psoriasis.
  2. Otezla, Warts and All, Racks Up Sales and Eyes Blockbuster Status.
  3. A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model.
  4. Real-World Experience With Apremilast in the Treatment of Adults With Moderate to Severe Plaque Psoriasis in Québec: A Claims-Based Analysis of Drug Utilization and Healthcare Resource Utilization.
  5. Real-world treatment patterns, resource use and cost burden of multiple myeloma in Portugal.
  6. Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis.
  7. Pharmacy costs of specialty medications for plaque psoriasis in the United States.
  8. Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies.
  9. Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden.
  10. Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status.